MIA (melanoma inhibitory activity): A potential serum marker for rheumatoid arthritis

Rheumatology

Volumn 38, Issue 2, 1999, Pages 148-154

  Muller Ladner U ^a,b   Bosserhoff, A K ^b   Dreher, K ^a   Hein, R ^c   Neidhart, M ^d   Gay, S ^d   Scholmerich J ^a   Buettner, R ^b   Lang, B ^a  

^a Department of Internal Medicine I   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cartilage; Joint destruction; MIA; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; INFLAMMATION; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MELANOMA; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SERUM;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MELANOMA; NEOPLASM PROTEINS; SKIN NEOPLASMS;

EID: 0032746407     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.2.148     Document Type: Article

References (35)

1. Blesch A, Bosserhoff AK, Apfel R et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994;54:5695-701.
2. Koehler MR, Bosserhoff A, von Beust G et al. Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics 1996;35:265-7.
3. Bosserhoff AK, Hein R, Bogdahn U, Buettner R. Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 1996; 271:490-5.
4. Van Groningen JJ, Bloemers HP, Swart GW. Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res 1995;55:6237-43.
5. Bosserhoff AK, Kondo S, Moser M et al. Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dynam 1997;208:516-25.
6. Dietz U, Sandell LJ. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem 1996;271:3311 6.
7. Bosserhoff AK, Kaufmann M, Kaluza B et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997,57:3149 53.
8. Bosserhoff AK, Lederer M, Kaufmann M et al. MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res; in press.
9. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993;52:S39-47.
10. Müller-Ladner U, Gay RE. Gay S. Cysteine proteases in arthritis and inflammation. In: James MNG. McKerrow JH, eds. Perspectives in drug discovery and design. ESCOM Science Publishers, Leiden, The Netherlands 1996;6:87-98.
11. Hummel KM, Neidhart M, Vilim V, Hauser N, Gay RE, Gay S. Analysis of cartilage oligomeric protein in synovial fibroblasts and fluids. Br J Rheumatol 1998;37:721-8.
12. Asahara H, Asanuma M, Ogawa N, Nishibayashi S, Inoue H. High DNA-binding activity of transcription factor NFκB in synovial membranes of patients with rheumatoid arthritis. Biochem Mol Biol Int 1995;37:827-32.
13. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.
14. Marok R, Winyard PG, Coumbe A et al. Activation of the transcription factor nuclear factor κB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
15. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996;35:1263 8.
16. Rodeck U, Herlyn M. Growth factors in melanoma. Cancer Metastasis Rev 1991;10:89 101.
17. Colombo MP, Maccalli C, Mattei S, Melani C, Radrizzani M, Parmiani G. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res 1992;2:181 9.
18. Verschure PJ, Van Noorden CJ, Van Marle J. Van den Berg WB. Articular cartilage destruction in experimental inflammatory arthritis: Insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes. Histochem J 1996;28:835-57.
19. Trippel SB. Growth factor actions on articular cartilage. J Rheumatol 1995;43:129 32.
20. Pelletier JP, DiBattista JA, Roughley P, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage destruction. Rheum Dis Clin North Am 1993;19:545-68.
21. Woessner JF Jr, Howell DS. Joint cartilage degradation: basic and clinical aspects. New York: Marcel Dekker, 1993.
22. Häuselmann HJ, Flechtenmacher J, Michal L et al. The superficial layer of human articular cartilage is more susceptible to interleukin-1-induced damage than the deeper layers. Arthritis Rheum 1996;39:478 88.
23. Menter DG, Herrmann JL, Nicolson GL. The role of trophic factors and autocrinc/paracrine growth factors in brain metastasis. Clin Exp Metastasis 1995;13:67-88.
24. Borden P, Solymar D, Sucharczuk A, Lindman B, Cannon P, Heller RA. Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes. J Biol Chem 1996;271:23577-81.
25. Keyszer GM, Heer AH, Kriegsmann J et al. Comparative analysis of cathepsin L, cathepsin D, and collagenase mRNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis Rheum 1995;38:976 84.
26. Ronday HK, Smits HH, Quax PHA et al. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997;36:9 15.
27. Boike G, Lah T, Sloane BF et al. A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res 1992;1:333-40.
28. Jean D, Hermann J, Rodrigues-Lima F, Barel M, Balbo M, Frade R. Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: amino-acid-sequence identities with procathepsin L. Biochem J 1995;312:961-9.
29. Kageshita T, Yoshii A, Kimura T et al. Biochemical and immunohistochemical analysis of cathepsins B, H, L, and D in human melanocytic tumours. Arch Dermatol Res 1995;287:266-72.
30. Mayer P, Schmid H, Schaber B, Fierlbeck G. Tumor-associated cysteine proteinase activities in human melanoma cells and fibroblasts of different origin. Eur J Cell Biol 1997;73:344-51.
31. Mueller BM. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 1996;213:65-80.
32. Schweiger A, Stabuc B, Popovic T, Turk V, Kos J. Enzyme-linked immunosorbent assay for the detection of total cathepsin H in human tissue cytosols and sera. J Immunol Methods 1997;201:165-72.
33. Durko M, Navab R, Shibata HR, Brodt P. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta 1997;1356:271-80.
34. Vaisanen A, Tuominen H, Kallioinen M, Turpeenniniemi-Hujainen T. Matrix metalloproteinase-2 (72kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996;180:283-9.
35. Huet G, Flipo RM, Colin C et al. Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1993;36:772-80.